For the record - Attached BelowAbstract
Background
Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CF33-hNIS-antiPDL1.
Study Design
CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against five PDAC cell lines was tested at various doses (multiplicity of infection (MOI) = 0.01, 0.1, 1, 10). Production and blockade function of virus-encoded anti-PD-L1 antibody were verified using immunoblot, immunoprecipitation, and PD-1/PD-L1 bioassay. In vivo mouse models of PC, with or without subcutaneous (SC) tumors created by injecting AsPC-1-ffluc cells into nude mice, were treated with PBS or a single dose (1x105 plaque-forming units) of either intraperitoneal (IP) or intravenous (IV) injections of CF33-hNIS-antiPDL1. Mice with PC tumors were treated on days 0, 2, or 14 following tumor implantation.
Results
CF33-hNIS-antiPDL1 killed PDAC cells in a dose-dependent manner achieving >90% cell killing by day 8. Cells infected with CF33-hNIS-antiPDL1 produced bioactive anti-PD-L1 antibody which blocked PD-1/PD-L1 interaction. In vivo, single dose of virus reduced tumor burden and prolonged survival of treated mice. It was observed that IP administration of CF33-hNIS-antiPDL1 was more effective than IV administration.
Conclusion
CF33-hNIS-antiPDL1 virus is effective in infecting and killing human PDACs and producing functional anti-PD-L1 antibody. IP delivery of CF33-hNIS-antiPDL1 effectively reduces peritoneal tumor burden and improves survival after only one dose and is superior to IV delivery.
- Forums
- ASX - By Stock
- IMU
- Latest Email from Leslie (11 Feb 2020 @ 9am)
Latest Email from Leslie (11 Feb 2020 @ 9am), page-5
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $364.4M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.8¢ | $114.6K | 2.351M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 1433216 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 1648949 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 1696471 | 0.048 |
44 | 4487531 | 0.047 |
57 | 4585839 | 0.046 |
57 | 6161161 | 0.045 |
19 | 3003966 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 1062955 | 22 |
0.050 | 4439678 | 27 |
0.051 | 6215011 | 15 |
0.052 | 1534519 | 12 |
0.053 | 1106781 | 10 |
Last trade - 11.24am 01/10/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online